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Background: The PI3K pathway is hyperactivated in many cancers, including 70 % of breast cancers. Pan- and
isoform-specific inhibitors of the PI3K pathway are currently being evaluated in clinical trials. However, the clinical
responses to PI3K inhibitors when used as single agents are not as efficient as expected.
Methods: In order to anticipate potential molecular mechanisms of resistance to the p110α isoform-selective
inhibitor BYL719, we developed resistant breast cancer cell lines, assessed the concomitant changes in cellular
signaling pathways using unbiased phosphotyrosine proteomics and characterized the mechanism of resistance
using pharmacological inhibitors.
Results: We found an increase in IGF1R, IRS1/IRS2 and p85 phosphorylation in the resistant lines. Co-immunoprecipitation
experiments identified an IGF1R/IRS/p85/p110β complex that causes the activation of AKT/mTOR/S6K and
stifles the effects of BYL719. Pharmacological inhibition of members of this complex reduced mTOR/S6K
activation and restored sensitivity to BYL719.
Conclusion: Our study demonstrates that the IGF1R/p110β/AKT/mTOR axis confers resistance to BYL719 in
PIK3CA mutant breast cancers. This provides a rationale for the combined targeting of p110α with IGF1R or
p110β in patients with breast tumors harboring PIK3CA mutations.
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The phosphatidylinositol 3-kinase (PI3K) signaling cascade
is a major pathway inducing hallmarks of cancer [1]. Of the
three main classes of lipid kinases in the PI3K family, the
class I enzymes are often altered in human cancers [2].
Class IA PI3Ks include regulatory and catalytic subunits
where the regulatory p85 maintains the catalytic p110 in a
low activity state [2]. p110α and p110β are expressed ubi-
quitously whilst p110δ is restricted to immune cells. Class
IA PI3Ks primarily generate phosphatidylinositol-3,4,5-tris-
phosphate (PIP3) from phosphatidylinositol-4,5-bispho-
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(http://creativecommons.org/publicdomain/zeAKT and activation of downstream kinases essential for cell
growth, proliferation, survival, and metabolism [3, 4].
An estimated 70 % of breast cancers show hyperactiva-
tion of the PI3K pathway. Amplification and/or mutation
of PIK3CA, the gene encoding the p110α catalytic subunit,
occurs in 20–40 % of breast cancers, leading to an in-
crease in activity of the enzyme. Moreover, expression of
mutant PIK3CA in the mouse mammary gland induces
heterogeneous mammary tumors with features resembling
human breast cancer [5, 6]. Further mechanisms of PI3K
pathway hyperactivation include phosphatase and tensin
homolog (PTEN) loss of function (30 % of breast cancers),
activation of receptor tyrosine kinases (RTK), and the
amplification or mutation of AKT [7].
Not surprisingly, members of the PI3K pathway are at-
tractive therapeutic targets in oncology. Although a broad
range of PI3K inhibitors are currently in clinical trials, thes distributed under the terms of the Creative Commons Attribution 4.0
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bust than expected. Isoform-selective PI3K inhibitors are
highly specific and thus can be used at higher concentra-
tions than pan-PI3K inhibitors, resulting in a more robust
target inhibition, while limiting side-effect complication
[8]. However, the combination of isoform-selective PI3K
inhibitors with additional agents may require the use of
lower concentrations to avoid potential toxicities.
Screening of a panel of cancer cell lines has revealed
the hypersensitivity of cells with PIK3CA mutations to
the α-specific inhibitor BYL719 [9]. Early clinical trials
evaluating BYL719 were restricted to patients with
PIK3CA-mutated solid tumors and showed promising
clinical activity with prolonged disease stabilization and
tumor shrinkage [10]. Anticipating potential mecha-
nisms of resistance to PI3K α-specific inhibitors such as
BYL719 is crucial in order to rationally stratify patients
for such therapy and design efficacious combinations.
To identify potential molecular mechanisms of resist-
ance, we developed BYL719-resistant breast cancer cell
lines and used unbiased global phosphoproteomic ap-
proaches to assess changes in signaling molecules and
pathways as well as functional assays. We found that insu-
lin growth factor receptor (IGF1R)/p110β-evoked AKT/
mammalian target of rapamycin (mTOR)/S6K activation
stifles the effects of BYL719. Combination of p110α inhib-
ition with inhibitors of IGF1R or p110β circumvents
BYL719 resistance. Thus, we have discovered an import-
ant mechanism of resistance to PI3K α-specific inhibition
and propose that the combination of the described in-
hibitors may be more efficacious in treating human
breast tumors than any of the single agents.
Materials and methods
Cell lines
Human cell lines T47D and MCF7 were obtained from
the American Type Culture Collection (Manassas, VA,
USA), were authenticated by single nucleotide poly-
morphism fingerprinting, and were generally used within
20 passages. The cell lines were maintained in RPMI
medium supplemented with 10 % fetal bovine serum,
10 μg/ml human insulin solution, 100 IU/ml penicillin,
and 100 μg/ml streptomycin. All lines were maintained
at 37 °C with 5 % CO2. To develop resistant models, par-
ental cell lines were chronically treated with IC90: (90 %
inhibitory concentrations) of BYL719 (2 μM for T47D and
5 μM for MCF7) over a period of 5–6 months until resist-
ance occurred. Fresh media were provided every 2 days.
Antibodies and reagents
Antibodies used in this study were anti-pAKT Ser473,
anti-AKT, anti-pS6 Ser235/236, anti-S6, anti-pPRAS40
Thr246, anti-pERK1/2 Thr202/Tyr204, anti-ERK1/2, anti-
p110α, anti-p110β, anti-PTEN, anti-IRS1 (Insulin receptorsubstrate), anti-poly (ADP-ribose) polymerase (anti-
PARP), and anti-cleaved PARP from Cell Signaling
Technology (Danvers, MA, USA), anti-
phosphotyrosine 4G10 and anti-p85 from Millipore
(Billerica MA, USA) anti-pIGF1R/IR Tyr1162/1163
from Biosource (ThermoFisher Scientific, Waltham MA,
USA) and anti-IRS2 from Novus Biological (Littleton CO,
USA). BYL719, AEW541, RAD001, and MEK162 were
provided by Novartis Pharma AG (Basil, Switzerland).
MK2206, AZD6482, GSK2334470, CAL101, and
BMS354825 were purchased from Selleckchem (Hous-
ton TX, USA). All compounds used in vitro were dis-
solved in dimethyl sulfoxide (DMSO).
Sample preparation and phosphotyrosine
immunoprecipitation for liquid chromatography–mass
spectrometry
Cells were harvested in lysis buffer (200 mM ammonium
bicarbonate, pH 7.5, 8 M urea) supplemented with the
PhosStop phosphatase inhibitor cocktail Roche Diagnostics
(Rotkreuz, Switzerland), reduced and alkylated, and then
digested with Trypsin/LysC Promega (Madison WI, USA)
after dilution to 2 M urea. The peptides were acidified to
1 % TFA (trifluoroacetic acid) and desalted on SepPak C18
cartridges. Lyophilized peptides were dissolved in immuno-
precipitation buffer (50 mM ammonium bicarbonate,
pH 7.4, 150 mM NaCl, 1 % (w/v) octyl-β-D-glucopyrano-
side, and Roche protease and phosphatase inhibitors
(Complete and PhosStop, Roche Diagnostics, Rotkreuz,
Switzerland) and incubated with 200 μl of anti-
phosphotyrosine antibodies (PY99; SantaCruz, Dallas TX,
USA) for 16 hours at 4 °C. After elution of the beads with
0.1 % TFA, peptides were desalted on Poros R3 and further
purified on TiO2 microcolumns.
Analysis by liquid chromatography/tandem mass
spectrometry
The purified phosphopeptides were resuspended in 10 %
formic acid and injected onto a 15 cm × 75 μm ProteoPep
2 PicoFrit column (New Objectives, Woburn MA, USA)
connected to an LTQ-OrbiTrap Elite mass spectrometer
Thermo (ThermoFisher Scientific, Waltham MA, USA).
Buffer A consisted of H2O with 0.1 % formic acid and Buf-
fer B of 100 % acetonitrile with 0.1 % formic acid. Peptides
were separated using a two-step gradient, from 0 % B to
20 % B in 90 minutes and from 20 % B to 50 % B in 50 mi-
nutes. Data acquisition used a “Top 15 method”, where
every full mass spectrometry (MS) scan was followed by 15
data-dependent scans on the 15 most intense ions from the
parent scan. Full scans were performed in the OrbiTrap at
120,000 resolution with target values of 1E6 ions and 500
milliseconds injection time, while MS/MS scans were per-
formed in the ion trap with 1E4 ions and 200 milliseconds
injection time. Database searches were carried out with
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man Uniprot database (release 20130429, www.unipro-
t.org). Mass tolerances were set at 10 ppm for the
precursor and at 0.8 Da for the fragment ions. In the case
of ambiguous assignments, spectra were manually inter-
preted for confirmation of identity and localization of the
phosphorylation site using Scaffold (version 4.3; Proteome
Software, Portland OR, USA). Label-free quantification was
performed on duplicate liquid chromatography (LC)–MS
runs for each sample using Progenesis LC-MS (Non-
linear Dynamics Software, Newcastle-upon-Tyne, UK).
Normalized peptide intensities were added together for
each unique phosphorylated peptide with Mascot scores
exceeding 20, and used to calculate the log2 ratios between
samples for each unique phosphopeptide.
Immunoprecipitation and western blotting
Total proteins were extracted with 50 mM Tris–HCl,
pH 7.6, 150 mM NaCl, 1 % NP40, and Roche phosphat-
ase and protease inhibitor cocktail. Immunoprecipitation
was performed overnight at 4 °C on total protein lysates
with the indicated antibodies according to the supplier’s
recommendations. Protein G sepharose beads were then
added for 1 hour at 4 °C. Proteins were eluted with 50 μl
loading buffer (45 μl LDS sample buffer + 5 μl Reducing
Agent; Novex, ThermoFisher Scientific, Waltham MA,
USA,) and then boiled at 95 °C for 5 minutes. Immuno-
precipitates or 50 μg of proteins for a whole cell lysate
were loaded onto 4–12 % SDS-PAGE gels using the
NuPAGE system from Invitrogen (ThermoFisher Scien-
tific, Waltham MA, USA) (30 mA for 10 minutes and
50 mA for 1 hour 15 minutes) and then transferred onto
Invitrolon PVDF membranes in the Biorad Blotter sys-
tem (Hercules CA, USA), using blotting buffer contain-
ing 25 mM Tris-Base, 192 mM glycine, and 5 %
methanol (100 V for 30 minutes). Detection was by
chemiluminescence using the Western Bright ECL de-
tection kit Advansta (Menlo Park CA, USA). Immuno-
blots are representative of a minimum of three
independent experiments. An equal amount of protein
was loaded onto each gel and the immunoblots shown
in the same figure were developed simultaneously with
the same exposure time.
Cell number count
Standard cell growth was performed in 2 % fetal calf
serum medium with appropriate concentrations of the
indicated inhibitors using 24-well plates (50,000 cells/
well) and measured by sulforhodamide B staining
according to the manufacturer’s instructions (Sigma
Aldrich, St. Louis MO, USA). Dose-response experi-
ments were evaluated at day 3 and time course experi-
ments at days 3, 6, and 9. In the time course
experiments, cells were plated and treatments withDMSO vehicle (VHC) or the indicated inhibitors started
6 hours later. VHC-treated resistant cell lines do not
have BYL719 in the media all through the experiment.
Apoptosis assay
A total of 70,000 cells/well were seeded in six-well
plates. After overnight incubation, media were aspirated
and replaced with media with the indicated drugs. After
72 hours, the media were collected and cells were har-
vested, washed twice with cold phosphate-buffered saline
(PBS), and resuspended in Annexin binding buffer. Cells
were stained with propidium iodide (PI) and Annexin V
according to the manufacturer’s protocol (BD Biosci-
ences, San Jose, CA, USA).
Xenograft mouse experiment
Female Balb-c nude mice were used in compliance with
the Swiss laws on animal welfare and the animal proto-
cols were approved by the Swiss Cantonal veterinary
Office of Basel. MCF7 cells (5 × 106 cells) were sus-
pended in a 50 μl mixture of Matrigel (BD Biosciences,
San Jose CA, USA) and PBS (1/1), and were injected
subcutaneously into the right flank of female Balb-c
nude mice 6–8 weeks old. Mice were implanted with
estrogen pellets on the day of cell injection. Tumor-
bearing mice were randomized into six groups of five
or six mice based on tumor volume prior to initiation
of treatment, which started when the average tumor
volume was between 150 and 200 mm3. BYL719,
AEW541, and GSK2636771 were given orally daily.
BYL719 and GSK2636771 were dissolved in CMC/
Tween and AEW541 in NMP/PEG300 (1/9). VHC-
treated mice received a combination of CMC/Tween
and NMP/PEG300. Tumors were measured every 5 days
and tumor volumes calculated by the formula:
Tumor volume ¼ smaller diameterð Þ2  larger diameterð Þ  = 2:
Statistical analysis
For dose-response experiments, one-way analysis of vari-
ance analysis was performed using GraphPad Prism
(Graphpad, La Jolla CA, USA) 6.0 software to determine
GI50 (50 % growth inhibition) growth inhibition values.
For all analyses, reported values represent the means ±
standard error of the mean (SEM) of at least three inde-
pendent experiments. Data were tested with Student’s t
test and P <0.05 was considered statistically significant.
Results
Sustained mTOR activity leads to BYL719 resistance in
breast cancer cells harboring PIK3CA mutation
BYL719 was initially evaluated in clinical trials for
luminal breast cancer with PIK3CA mutations. Thus, to
Fig. 1 Generation of BYL719-resistant breast cancer cell lines. a Immunoblots of lysates from T47D and MCF7 cells treated for 1 hour with increasing
concentrations of BYL719. Immunoblot quantification used ImageJ software (developed at the U. S. National Institutes of Health and available on the
Internet at http://rsb.info.nih.gov/nih-image/). b Schematic of the generation of BYL719-resistant breast cancer cell lines. Parental cells were treated
chronically with respective IC90 (90 % inhibitory concentrations) of BYL719 for a period of 5–6 months. c Curves showing BYL719 dose-
responses of parental and resistant lines after 3 days of treatment. Cell number was evaluated using the sulforhodamide B assay. GI50 (50
% growth inhibition) values were calculated using GraphPad Prism 6 software. Data are mean ± SEM (n >3). d Immunoblots of lysates
from parental and resistant cells treated with respective IC90 (90 % inhibitory concentrations) of BYL719 as indicated. MCF7p MCF7-
parental, MCF7r MCF7-resistant, SEM standard error of the mean, T47Dp T47D-parental, T47Dr T47D-resistant
Leroy et al. Breast Cancer Research  (2016) 18:41 Page 4 of 13investigate the mechanisms of resistance to BYL719, we
selected the BYL719-sensitive luminal human breast
cancer cell lines T47D and MCF7 harboring the H1047R
and E545K PIK3CA hotspot mutations, respectively. We
first calculated IC50 (50 % inhibitory concentration)
values for BYL719 using pAKT Ser473 immunoblotting
as a readout of p110α inhibition (Fig. 1a). We next de-
veloped BYL719-resistant cell lines by chronically treat-
ing parental T47D and MCF7 cells with BYL719 at IC90
(2 μM for T47D; 5 μM for MCF7) (Fig. 1b). BYL719
blocked T47D and MCF7 cells in the G1 phase, causing
proliferation arrest for 5–6 weeks (data not shown).
Thereafter, inhibition of PI3K by chronic BYL719 treat-
ment was overcome and cells started to grow. Four monthslater, cells became resistant to the compound, with a
change in GI50 values relative to parental lines of 5.2-fold
for T47D-resistant (T47Dr) cells and 9.4-fold for MCF7-
resistant (MCF7r) cells (Fig. 1c). GI50 values calculated in
our experiments correlate with values reported by Vora
et al. [11]. IC50 values for BYL719 measured by the AKT
phosphorylation level are different between these two cell
lines, but the GI50 values for BYL719-mediated inhibition
of cell proliferation are identical. This suggests a differential
requirement between these two cell lines for AKT signaling
to drive cell proliferation (Fig. 1a, c). Interestingly, resistant
cells cultured for 2 weeks in the absence of BYL719 com-
pletely lost their resistance, showing that the mechanism of
resistance was reversible (see Additional file 1A).
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nents of the PI3K pathway in resistant and parental cells.
Phosphorylation of AKT at Ser473 was reduced to a
similar extent in parental and resistant cells (Fig. 1d). In
some experiments we did see a slightly higher level of
AKT phosphorylation in the resistant cells compared
with the parental cells after 6–24 hours of treatment (as
in Fig. 1d), but this was not consistently observed, lead-
ing us to conclude that the pathway responses at the
level of Akt were similar between parental and resistant
cells. In contrast, whereas a 70 % decrease in S6 phos-
phorylation at Ser235/236 was observed in parental cell
lines, a smaller 20 % decrease occurred in resistant cells
(Fig. 1d; see also Additional file 1B) suggesting that sus-
tained mTOR activity leads to BYL719 resistance in
PIK3CA mutant breast cancer cells.
Phosphoproteomics revealed increases in IGF1R, IRS, and
p85 PI3K tyrosine phosphorylation in resistant cell lines
Unbiased tyrosine phosphoproteomics was used to iden-
tify the molecular mechanism underlying sustained
mTOR activity in BYL719-resistant lines. Combined to-
tals of 398 and 475 phosphotyrosine peptides, derived
from 266 and 307 proteins, were identified in parental
and resistant T47D and MCF7 cells, respectively (see
Additional files 2 and 3). Increased phosphorylation on
tyrosine phosphosites of IGF1R, IRS1, IRS2, and p85
PI3K were found in T47Dr and MCF7r cells relative to
the parental lines (Fig. 2a). Immunoblotting analysis
demonstrated that the increases in IRS (Insulin receptor
substrate) phosphorylation correlated with increases in
IRS1 and IRS2 protein expression in T47Dr and MCF7r
cells, respectively (Fig. 2b). Treatment of T47Dr and
MCF7r cells with BYL719 for 24 hours increased IRS1
and IRS2 tyrosine phosphorylation but had no effect on
IRS1 and IRS2 protein expression levels (Fig. 2b, c).
Moreover, BYL719 treatment also induced an increase in
p85 PI3K tyrosine phosphorylation in the resistant lines
(Fig. 2c). Interestingly, insulin withdrawal abrogated IRS1,
IRS2, or p85 tyrosine phosphorylation observed in resistant
cells upon BYL719 treatment, suggesting that the insulin/
IGF1R/IRS pathway contributes to BYL719 resistance.
Taken together, our results suggest an important effect of
the IGF1R/IRS tandem on resistance to BYL719.
IGF1R mediates resistance to BYL719
The phosphoproteomic data suggested the insulin/
IGF1R/IRS axis as a driver of resistance to BYL719.
Interestingly, removal of insulin from the culture media
restored the sensitivity of resistant cells to BYL719
(Fig. 3a). This observation correlates with the decrease
of tyrosine phosphorylation of IRS1, IRS2 and p85 in re-
sistant cell lines upon insulin withdrawal (Fig. 2c). We
then compared the effects of BYL719 and the IGF1Rinhibitor AEW541, alone or in combination, on parental
and resistant cell lines. Combined inhibition of p110α and
IGF1R reversed BYL719 resistance (Fig. 3b) and increased
cell death of resistant cells, as shown by an increase in
PARP cleavage and apoptosis assay (PI and Annexin V)
(see Additional file 4A, B). Although the combination
BYL719/AEW541 resulted in significant growth inhib-
ition, MCF7 cells appear to be more dependent on the
IGF1R pathway as suggested by the sensitivity of MCF7
cells to AEW541 when used as a single agent (Fig. 3b).
This observation is in line with previous studies [12]
showing that the PIK3CA E545K mutant (as in
MCF7) requires IRS tyrosine phosphorylation to be
fully activated and drive the downstream pathway.
Combination of BYL719 with either insulin with-
drawal or AEW541 treatment resulted in decreases in
AKT Ser473 and S6 Ser235/236 phosphorylation
(Fig. 3c). Moreover, either insulin withdrawal in the ab-
sence of BYL719 or AEW541 single-agent treatment de-
creased AKT phosphorylation in MCF7 cells but not in
T47D cells, confirming the dependency of MCF7 cells on
IGF1R-driven IRS tyrosine phosphorylation. These data
show that IGF1R-evoked mTOR activation is a key driver
of resistance to BYL719 in these models.
Activation of IGF1R/p110β/AKT/mTOR produces
resistance to BYL719
To address the mechanism of resistance to BYL719, we
used inhibitors of molecules and pathways known to result
in resistance to PI3K inhibition (Fig. 4a). Concentrations of
BYL719 that have been shown to inhibit the other p110 iso-
forms [9] also downregulated mTOR activity (Fig. 4b).
PDK1-specific, AKT-specific, and p110β-specific inhibitors
in combination with BYL719 abrogated S6 and PRAS40
phosphorylation, whereas the p110δ inhibitor did not
(Fig. 4c; see also Additional file 5). These data suggest that
an IGF1R/p110β/AKT/mTOR pathway increases resist-
ance to BYL719. Inhibition of IGF1R, p110β, PDK1, AKT,
or mTOR in combination with BYL719 reduced T47Dr
and MCF7r cell growth, whereas inhibition of p110δ,
MEK, or Src family kinases (SFK) showed only a partial ef-
fect (Fig. 4d). Accordingly, MEK and SFK inhibition in
combination with BYL719 did not decrease S6 or PRAS40
phosphorylation (see Additional file 6). Taken together, our
data highlight the activation of IGF1R/p110β/AKT/mTOR
as a mechanism of resistance to BYL719 in PIK3CA-mu-
tated breast cancer cells.
Phosphorylated IRS and p85 recruit p110β in BYL719-
resistant lines
We next assessed the mechanism of p110β activation in
BYL719-resistant cell lines. Because we had found that
IGF1R/IRS mediates resistance to BYL719 and that p85
and IRS tyrosine phosphorylation are increased in an
AB C
Fig. 2 BYL719 resistance correlates with increases in IGF1R, IRS (insulin receptor substrate), and p85 PI3K tyrosine phosphorylation. a Fold changes in
tyrosine phosphorylation in resistant cells compared with parental cells without BYL719 treatment, expressed as the log2 resistant/parental ratio and
displayed in rank order from low to high. Graphs were generated with TIBCO Spotfire software (TIBCO Software, Boston MA, USA). b Immunoblots of
lysates from parental and resistant lines treated for 24 hours with 2 μM (T47D) or 5 μM (MCF7) BYL719 as indicated. c Bar graphs representing intensities
of phosphopeptides bearing the indicated tyrosine phosphosites as identified by LC-MS/MS. T47D and MCF7 parental and resistant cells were treated for
24 hours with respective IC90 concentrations of BYL719 in the presence or absence of insulin in the media. Data are mean ± STD of technical duplicates
(n >2, *P <0.05, **P <0.01, ***P ˂0.001). MCF7p MCF7-parental, MCF7r MCF7-resistant, PI3K phosphatidylinositol 3-kinase, T47Dp T47D-parental,
T47Dr T47D-resistant
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pothesized that an IGF1R/IRS/p85 complex, active through
tyrosine phosphorylation of IRS and p85, recruits and acti-
vates p110β. To test this possibility, we treated parental andresistant cells with BYL719 alone or in combination with
AEW541 and performed IRS1 (T47D lysates), IRS2 (MCF7
lysates), or p85 immunoprecipitation, followed by anti-
phosphotyrosine immunoblotting. This confirmed the
A B
C
Fig. 3 BYL719 resistance of breast cancer cell lines is dependent on IGF1R activity. a BYL719 dose-responses of parental and resistant lines after
3 days of treatment in the presence or absence of insulin in the culture media. Cell numbers were evaluated using the sulforhodamide B assay.
GI50 (50 % growth inhibition) values were calculated using GraphPad Prism 6 software. Data are mean ± SEM (n = 3). b Proliferation of parental
and resistant cells treated with vehicle (VHC), AEW541 (1 μM), BYL719 (IC90), or a combination of BYL719 and AEW541 for 9 days. Cell numbers
were evaluated using the sulforhodamide B assay. Data are mean ± SEM (n >3, *P <0.01, **P <0.001). c Immunoblots of lysates from parental and
resistant cells treated for 24 hours as indicated. BYL719 (IC90) and AEW541 (1 μM). MCF7p MCF7-parental, MCF7r MCF7-resistant, T47Dp T47D-
parental, T47Dr T47D-resistant
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ously observed in resistant cells upon BYL719 treatment
(Figs. 2c and 5a, b). Interestingly, we observed coimmuno-
precipitation of p110β/p85 with IRS when IRS and p85 were
tyrosine phosphorylated. Conversely, the IRS/p110β/p85
complex was disrupted upon IGF1R inhibition (Fig. 5a, b).
Loss of PTEN expression was demonstrated recently in
metastases from a patient showing relapsed response toBYL719 therapy [13], and PTEN null breast cancers have
been shown to be driven by p110β and not by p110α [14,
15]. We tested whether the p110β dependency of BYL719-
resistant cells is due to PTEN loss but found no difference
in PTEN expression between resistant and parental lines
(see Additional file 7). Our results indicate that IRS and
p85 tyrosine phosphorylation by IGF1R are necessary for




Fig. 4 Activation of IGF1R/p110β/AKT/mTOR produces resistance to BYL719. a Compounds used and their respective targets. b Immunoblots of
lysates from parental and resistant cells treated for 24 hours as indicated. c Immunoblots of lysates from parental and resistant cells treated for
24 hours with the respective IC90 concentrations of BYL719 and/or 1 μM of the indicated compounds. d Proliferation of parental and resistant
cells treated with the respective IC90 concentrations of BYL719 in combination with 1 μM of the indicated inhibitors. Cell numbers were
evaluated using the sulforhodamide B assay. Data are mean ± SEM (n >2, *P <0.05, **P <0.01). DMSO dimethyl sulfoxide, IGF1R insulin growth
factor receptor, MCF7p MCF7-parental, MCF7r MCF7-resistant, mTOR mechanistic target of rapamycin, SFK Src family kinases, T47Dp T47D-parental,
T47Dr T47D-resistant
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dependent manner
We next tested the effect of p110β inhibition alone or in
combination with BYL719 on the survival of parental
and resistant T47D and MCF7 cells. Notably, combined
p110α and p110β inhibition decreased cell numbers in
both parental and resistant cell lines (Fig. 5c). Inhibition
of p110β had no effect on T47Dr, MCF7-parental
(MCF7p), or MCF7r cell lines (Fig. 5c). This inhibition
partially decreased the number of T47D-parental
(T47Dp) cells (Fig. 5c), which is in agreement with the
observed coimmunoprecipitation of p110β with IRS1only in T47Dp cells (Fig. 5a). We conclude that p110β
inhibition circumvents the resistance of PIK3CA-mu-
tated breast cancer cells to BYL719. We next confirmed
our observations in an in vivo xenograft mouse
experiment with MCF7 cells. A combination of
BYL719 with IGF1R (AEW541) or p110β inhibitors
(GSK2636771 was used as a p110β inhibitor instead of
AZD6482 to ensure better tolerability in combination)
strongly decreased tumor growth whereas either agent
alone did not (Fig. 5d). Our results show that IGF1R-





Fig. 5 p110β is activated in an IGF1R/IRS (insulin receptor substrate)-dependent manner and promotes resistance to BYL719. a Immunoblots of
coimmunoprecipitated p110β, p110α, or p85 PI3K from lysates of parental and resistant cells treated for 24 hours with or without IC90
concentrations of BYL719 combined with or without 1 μM of AEW541. b Immunoblots of immunoprecipitated p85 PI3K antibody from lysates of
parental and resistant cells treated for 24 hours with IC90 concentrations of BYL719 combined with or without 1 μM AEW541. c Proliferation of
parental and resistant cells treated with vehicle (VHC), AZD6482 (1 μM), BYL719 (IC90), or a combination of BYL719 and AZD6482 for 9 days. Cell
numbers were evaluated using the sulforhodamide B assay. Data are mean ± SEM (n >3, *P <0.01, **P <0.001). d Growth curves of MCF7 tumors
from Balb-c nude mice treated with VHC, 25 mg/kg BYL719 (p110α inhibitor) daily, 75 mg/kg AEW541 (IGF1R inhibitor) daily, 100 mg/kg
GSK2636771 (p110β inhibitor) daily, alone or in combination as indicated. Data are mean ± SEM (n >5, *P <0.001). IP immunoprecipitation, MCF7p
MCF7-parental, MCF7r MCF7-resistant, T47Dp T47D-parental, T47Dr T47D-resistant
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Mechanism-based inhibitors that target cancer depend-
encies have been shown to be effective and well tolerated
in several clinical trials but, unfortunately, most did not
provide long-lasting therapy. Emergent resistance can
result in relapse of disease within a few months [16, 17].
Anticipation of potential molecular mechanisms of re-
sistance to a given targeted therapy is therefore crucial
for the selection of patients who may benefit from the
treatment and, when necessary, for the rational design of
combination therapies [18].
The PI3K pathway is one of the most attractive
therapeutic targets and numerous inhibitors are being
evaluated in clinical trials [8]. Pan-PI3K inhibitors are
often used at a dose that does not completely block
PI3K activity, which may not result in acceptable efficacy.
Isoform-specific inhibitors are considered to have a better
therapeutic index than dual PI3K/mTOR or pan-PI3K
inhibitors currently used in the clinic [10]. Accordingly,
α-specific PI3K inhibitors like BYL719 have shown prom-
ising preclinical and clinical results with cancers harboring
mutated and/or amplified PIK3CA [9, 10]. Unfortunately,
clinical responses to α-specific PI3K inhibitors as single
agents have not met expectations because of intrinsic and/
or developed resistance. Therefore, in addition to aiding
patient stratification and the identification of appropriate
biomarkers, anticipating mechanisms of resistance to
PI3K inhibition is essential for the rational design of com-
bination therapies.
In the present study, we have discovered that IGF1R-
evoked p110β activation compensates for selective
p110α inhibition. Evidence is provided by our findings
that inhibition of members of the IGF1R/p110β/AKT/
mTOR pathway improves the efficacy of p110α inhib-
ition. These data provide a rationale for combining α-
specific PI3K inhibitors with inhibitors of the IGF1R/
p110β/AKT/mTOR axis (Fig. 6).
Various mechanisms of resistance to dual PI3K/mTOR
inhibitors have been reported, such as MYC amplifica-
tion [19, 20], MEK/ERK/RSK pathway activation [21], or
BCL2, epidermal growth factor, and IGF1R [22]. Re-
cently, mTORC [23] or CDK4/6 [11] inhibition has been
shown to sensitize PIK3CA mutant breast cancers to α-
specific PI3K inhibitors. PTEN loss has also been identi-
fied as the basis of resistance to BYL719 in a small set of
patients with breast cancer that progressed further after
an initial beneficial response to BYL719 [24]. Recently,
measurement of PIP3 levels revealed that the efficiency
of p110α inhibition was compensated by the activation
of p110β in an early adaptive response which mitigates
the anti-tumor efficacy of BYL719 [25]. Here, we dem-
onstrate the importance of p110β in PIK3CA-mutated
breast cancer cell lines. Although in PTEN null breast
cancers, p110β activity was induced by G proteincoupled receptor (GPCR) [14, 15], in our models of re-
sistance to BYL719, p110β is activated in an IGF1R/IRS-
dependent manner and contributes to AKT and mTOR
activation, and ultimately to resistance to p110α inhib-
ition. Since blocking IGF1R was sufficient to abrogate
the resistance, it is likely that GPCRs are not involved in
p110β activation in our system.
Our data suggest that inhibition of various compo-
nents of the IGFR/PI3K/mTOR pathway is more effica-
cious than inhibition of p110α alone. Vertical inhibition
of members of the same pathway was shown previously
to efficiently abrogate mitogen-activated protein kinase
(MAPK) signaling [26–28], and this scenario has also
been suggested recently for the PI3K pathway [11, 29].
We find that inhibition of AKT reverses resistance to
BYL719. This observation is surprising as resistant cells
showed complete reduction of AKT phosphorylation
upon treatment with BYL719, suggesting that AKT was
inactive. Equally surprising was the observation that
PRAS40, a direct substrate of AKT, was phosphorylated
on Thr246 but AKT was not. Further analysis of AKT
phosphorylation sites by LC-MS/MS may resolve this
paradox.
BYL719-resistant breast cancer cells showed a high de-
pendency on the insulin pathway; removal of insulin
from the medium was sufficient to abrogate resistance.
Hyperglycemia is the most frequently observed side ef-
fect in patients treated with PI3K inhibitors and is an in-
dication of effective PI3K inhibition. Our data highlight
the importance of insulin levels for the response to
BYL719 and its potential implication in intrinsic or de-
veloped resistance. Thus, a combination of PI3K and
IGF1R inhibitors would be an attractive therapeutic
strategy to counteract insulin-dependent resistance.
IGF1R inhibition blocks both the PI3K and the
MAPK pathways when RAF and RAS are not mu-
tated, suggesting that combination of p110α and
IGF1R inhibitors may be more efficacious. Given that
hyperglycemia has been reported for both PI3K and
IGF1R inhibitors, combination of the two may result
in increased side effects. A phase I/II clinical trial has
started recently for patients with ovarian cancer or
breast cancer to evaluate the therapeutic benefit of
combining BYL719 with the anti-IGF1R antibody
AMG479 (ClinicalTrials.gov NCT01708161). The results
should indicate whether inhibition of IGF1R improves
BYL719 efficacy and is well tolerated by patients. Testing
a combination of continuous p110α inhibition and inter-
mittent IGF1R blockade is also warranted. Alternatively,
continuous treatment with BYL719 and either continuous
p110β inhibition or intermittent pan-PI3K inhibition may
reduce potential side effects.
In the era of precision medicine, the next challenge
will be to identify appropriate biomarkers that will
C D
A B
Fig. 6 Schematic model of IGF1R-evoked and p110β-evoked resistance to p110α inhibition in PIK3CA mutant breast cancer cells. Schematics illustrating
a the steady state of the PI3K pathway in PIK3CA mutant breast cancer, and b the identified feedback loop triggered by inhibition of p110α (BYL719)
and offset by c IGF1R (AEW541) or d p110β (AZD6482) inhibition at the cellular level. IGF1R insulin growth factor receptor, mTOR mechanistic target of
rapamycin, PI3K phosphatidylinositol 3-kinase
Leroy et al. Breast Cancer Research  (2016) 18:41 Page 11 of 13
Leroy et al. Breast Cancer Research  (2016) 18:41 Page 12 of 13indicate the right combination for the right patient. As
S6 phosphorylation and Rb phosphorylation have been
used recently to stratify patients who could benefit from
combination of BYL719 with mTOR or CDK4/6 inhibi-
tors, our data suggest that the level of expression and
the tyrosine phosphorylation of IRS1 and IRS2 would be
an excellent biomarker for the combination of p110α/
IGF1R or p110α/p110β inhibitors.
Conclusions
Our study demonstrates that p110β can produce resist-
ance to α-specific PI3K inhibition in an IGF1R/p85/IRS-
dependent manner in PIK3CA-mutant breast cancer.
These data provide a rationale for combining p110α
inhibition with IGF1R or p110β in patients with breast
tumors harboring PIK3CA mutations.
Additional files
Additional file 1: is a figure showing BYL719 resistance in PIK3CA
mutant breast cancer cells. A BYL719 resistance is reversible. BYL719
dose-response of parental and resistant lines (on or off BYL719 for
2 weeks) after 3 days of treatment. Cell numbers were evaluated using
the sulforhodamide B assay. GI50 values were calculated using GraphPad
Prism 6 software. Data are mean ± SEM (n >2). B pS6/S6 ratios in cells
treated with DMSO or BYL719 (IC90) for 24 hours. Data are mean of
pS6/S6 ratio ± SEM (n >3, *P <0.01). Immunoblots from three independent
experiments have been quantified using the ImageJ software. (PDF 117 kb)
Additional file 2: is a table presenting phosphopeptide intensity of
T47Dp with insulin but without BYL719; and T47Dr with or without
insulin treated for 24 hours with or without 2 μM BYL719. (PDF 258 kb)
Additional file 3: is a table presenting phosphopeptide intensity of
MCF7p with insulin but without BYL719; and MCF7r with or without
insulin treated for 24 hours with or without 5 μM BYL719. (PDF 308 kb)
Additional file 4: is a figure showing that a combination of BYL719/AEW541
triggers apoptosis in BYL719-resistant cell lines. A Anti-cleaved PARP (T47D) or
anti-PARP (MCF7) immunoblots of lysates from parental and resistant cells
treated for 24 hours as indicated. BYL719 (IC90), AEW541 (1 μM). B Parental and
resistant cells were treated with BYL719 (2 μM for T47D and 5 μM for MCF7),
AEW541 (1 μM), or the combination BYL719/AEW541 for 72 hours. Percentage
of apoptotic (Annexin V-positive and PI-negative) and necrotic cells
(Annexin V and PI-positive) are indicated. (PDF 158 kb)
Additional file 5: is a figure showing that activation of IGF1R/p110β/AKT/
mTOR produces resistance to BYL719. Immunoblots of lysates from parental
and resistant cells treated for 24 hours with the respective IC90 concentrations
of BYL719 and/or 1 μM of the indicated compounds. (PDF 142 kb)
Additional file 6: is a figure showing that inhibition of MEK or SFK
signaling pathways in combination with BYL719 does not alter mTOR-
sustained activity in resistant cells. Immunoblots of lysates from parental and
resistant cells treated for 24 hours with the respective IC90 concentration of
BYL719 and/or 1 μM of AEW541, 1 μM MK2206, 10 nM RAD001, 500 nM
MEK162, or 1 μM BMS354825. Immunoblots have been developed
simultaneously with the same time of exposure. (PDF 176 kb)
Additional file 7: is a figure showing that p110β activation does not
correlate with loss of PTEN. Immunoblots of lysates from parental and
resistant cells treated for 24 hours as indicated. BYL719 (IC90) and
AEW541 (1 μM). (PDF 140 kb)
Abbreviations
DMSO: Dimethyl sulfoxide; GPCR: G protein coupled receptor; IGF1R: Insulin
growth factor receptor; LC: Liquid chromatography; MAPK: Mitogen-activated
protein kinase; MCF7p: MCF7-parental; MCF7r: MCF7-resistant; MS: Massspectrometry; mTOR: Mechanistic target of rapamycin; PARP: Poly(ADP-ribose)
polymerase; PBS: Phosphate-buffered saline; PI: Propidium iodide;
PI3K: Phosphatidylinositol 3-kinase; PIP2: Phosphatidylinositol-4,5-bisphosphate;
PIP3: Phosphatidylinositol-3,4,5-trisphosphate; PTEN: Phosphatase and tensin
homolog; RTK: Receptor tyrosine kinases; SEM: Standard error of the mean;
SFK: Src family kinases; T47Dp: T47D-parental; T47Dr: T47D-resistant; VHC: Vehicle.
Competing interests
CL, PR, DB, CF, and HV are employees of Novartis Pharma AG. The remaining
authors declare that they have no conflict of interest.
Authors’ contributions
CL conceived the study, designed the experiments, collected, assembled,
and analyzed the data, interpreted the results, and wrote the manuscript.
PR contributed to resistant breast cancer cell development and in vivo
experiments and revised the manuscript. KC contributed to in vivo
experiments. DB performed MS data analysis and interpreted the results. CF
participated in conception of the study and revised the manuscript. HV and
MB-A conceived the study, designed the experiments, interpreted the results,
wrote the manuscript, and provided financial support. All authors read and
approved the final manuscript.
Authors’ information
CL and PR are postdoctoral fellows. KC is a laboratory technician with in vivo
expertise. DB and HV are laboratory heads in the Analytical Sciences and
Imaging group at Novartis with biochemistry, proteomic, and MS expertise.
CF is laboratory head at Novartis Oncology with expertise in the field of PI3K.
MB-A is group leader at the Friedrich Miescher Institute in the Mechanisms
of Cancers Department with expertise in breast cancer.
Acknowledgements
The authors would like to thank members of the MB-A laboratory for advice
and discussions, as well as L Cantley, M Maira, and S Brachmann for helpful
discussions. Research in the laboratory of MB-A is supported by the Novartis
Research Foundation, the European Research Council (ERC starting grant
243211-PTPsBDC), and the Krebsliga Beider Basel.
Author details
1Friedrich Miescher Institute for Biomedical Research, Maulbeerstraße 66,
4058 Basel, Switzerland. 2Novartis Institutes for Biomedical Research, Postfach,
CH-4002 Basel, Switzerland.
Received: 10 September 2015 Accepted: 16 March 2016
References
1. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a
theme. Oncogene. 2008;27(41):5497–510.
2. Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, et al.
Transformation of chicken cells by the gene encoding the catalytic subunit
of PI 3-kinase. Science. 1997;276(5320):1848–50.
3. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol
3-kinases as regulators of growth and metabolism. Nat Rev Genet.
2006;7(8):606–19.
4. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;
296(5573):1655–7.
5. Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff RD, Bentires-Alj M.
Luminal expression of PIK3CA mutant H1047R in the mammary gland
induces heterogeneous tumors. Cancer Res. 2011;71(13):4344–51.
6. Koren S, Bentires-Alj M. Mouse models of PIK3CA mutations: one mutation
initiates heterogeneous mammary tumors. FEBS J. 2013;280(12):2758–65.
7. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA,
et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3'
kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer
Res. 2010;16(14):3670–83.
8. Leroy C, Amante RJ, Bentires-Alj M. Anticipating mechanisms of resistance
to PI3K inhibition in breast cancer: a challenge in the era of precision
medicine. Biochem Soc Trans. 2014;42(4):733–41.
9. Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al.
Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719
Leroy et al. Breast Cancer Research  (2016) 18:41 Page 13 of 13and development of the patient stratification strategy for clinical trials. Mol
Cancer Ther. 2014;13(5):1117–29.
10. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K
inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol.
2013;10(3):143–53.
11. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, et al. CDK 4/6
inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer
Cell. 2014;26(1):136–49.
12. Hao Y, Wang C, Cao B, Hirsch BM, Song J, Markowitz SD, et al. Gain of
interaction with IRS1 by p110alpha-helical domain mutants is crucial for
their oncogenic functions. Cancer Cell. 2013;23(5):583–93.
13. Castel P, Juric D, Won H, Ainscough B, Ellis H, Ebbesen S, et al. Loss of PTEN
leads to clinical resistance to the PI3K inhibitor BYL719 and provides
evidence of convergent evolution under selective therapeutic pressure.
In: AACR annual meeting; San Diego, CA; 2014.
14. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, de Beaumont R, et al.
PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A. 2008;
105(35):13057–62.
15. Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, et al. Functional characterization
of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer
agent. Canc Discov. 2012;2(5):425–33.
16. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al.
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and
PIK3CA H1047R murine lung cancers. Nat Med. 2008;14(12):1351–6.
17. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J
Med. 2011;364(8):772–4.
18. Ramos P, Bentires-Alj M. Mechanism-based cancer therapy: resistance to
therapy, therapy for resistance. Oncogene. 2015;34(28):3617–26.
19. Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be
evaded by gene amplification along the MYC-eukaryotic translation initiation
factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A. 2011;108(37):E699–708.
20. Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, Lechtermann H,
et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K
inhibitors in cancer. Nat Chem Biol. 2011;7(11):787–93.
21. Serra V, Eichhorn PJ, Garcia-Garcia C, Ibrahim YH, Prudkin L, Sanchez G, et al.
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
J Clin Invest. 2013;123(6):2551–63.
22. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al.
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached
cancer cells. Cancer Cell. 2012;21(2):227–39.
23. Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, et al.
mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in
PIK3CA-mutant breast cancer. Sci Transl Med. 2013;5(196):196ra199.
24. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent
loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature.
2015;518(7538):240–4.
25. Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, et al.
Measurement of PIP3 levels reveals an unexpected role for p110beta in
early adaptive responses to p110alpha-specific inhibitors in luminal breast
cancer. Cancer Cell. 2015;27(1):97–108.
26. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1
mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci
U S A. 2009;106(48):20411–6.
27. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nature. 2010;468(7326):973–7.
28. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al.
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced
BRAF(V600E). Nature. 2011;480(7377):387–90.
29. Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C, et al. Vertical blockade of the
IGFR-PI3K/Akt/mTOR pathway for the treatment of hepatocellular
carcinoma: the role of survivin. Mol Cancer. 2014;13:2.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
